Oruka Therapeutics Inc. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.56 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 32.5× Oruka Therapeutics Inc. Common Stock's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| ORKA | VWO | |
|---|---|---|
Market Cap | $5.18B | $168.50B |
Volume | 490,798 | 5,873,453 |
Sector | Health | — |
52-Week High | $113.08 | $61.44 |
52-Week Low | $26.19 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $4.31B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VWO trades at $59.68, down slightly by 0.08% today. Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings are neutral. The ETF focuses on emerging markets, with exposure to Taiwan's AI and semiconductor sectors but faces headwinds from China's economic slowdown. Recent news highlights institutional buying interest, such as Allianz increasing its stake by 12.6% in Q3 2026.
Outlook is mixed: AI-driven growth in Taiwan offers upside, but China's weakness and concentration risks pose challenges. The ETF's low expense ratio of 0.06% appeals for cost-conscious investors, yet emerging market volatility requires caution. Key risks include regional economic instability and currency fluctuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →